Ligand Pharmaceuticals (NASDAQ: LGND) — Perfil da empresa, notícias e dados financeiros
Ligand Pharmaceuticals develops drug discovery technologies and partnerships to aid pharmaceutical companies in medicine development.
Ligand Pharmaceuticals
Ligand Pharmaceuticals (NASDAQ:LGND) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company's portfolio is diverse, covering areas such as gene therapy, oncology, antivirals, neuroscience, and immune disorders among others. Ligand's business model is based on leveraging its proprietary drug discovery technologies, including its patented Ph.D. (Phage Display) libraries, OmniAb® animal platforms for antibody discovery, and LTP (Liver Targeting Prodrug) technology, to partner with or license to other pharmaceutical companies. These collaborations are designed to generate recurring revenue streams through royalties, milestones, and licensing fees. The company's objective is to continue expanding its technology portfolio, thereby increasing its partnerships and licensing agreements, to ultimately improve patient care by aiding in the discovery and development of novel therapeutics.
Resumo
Operações
Produtos e/ou serviços de Ligand Pharmaceuticals
- OmniAb platform, a comprehensive antibody discovery suite offering diverse, fully human antibodies for high-potential drug targets.
- Captisol, a proprietary chemical modification of cyclodextrins that improves the solubility and stability of drugs.
- Pelican Expression Technology, a robust protein expression platform designed for producing difficult-to-express proteins and antibodies.
- LTP Technology, a liver-targeting prodrug technology that enhances the delivery and efficacy of existing drugs.
- Vernalis Design Platform, offering structure-based drug discovery expertise, fragment screening, and computational chemistry to develop novel therapeutics.
- Icagen Ion Channel Technology Service, providing specialized expertise in ion channel and transporter drug discovery and development.
equipe executiva do Ligand Pharmaceuticals
- Todd C. DavisCEO & Director
- Octavio EspinozaChief Financial Officer
- Andrew T. ReardonChief Legal Officer & Secretary
- Paul J. HaddenSenior Vice President of Investments & Business Development
- Melanie J. HermanExecutive Director of Investor Relations and Financial Planning & Analysis
- Marjorie FackovecHead of People Operations
- Keith MarschkeSenior Vice President of Biology & Scientific Affairs
- Vincent D. AntleSenior Vice President of Technical Operations & QA - Capitsol
- Karen R. ReevesSenior VP of Investments & Head of Clinical Strategy
- Richard B. BaxterSenior VP of Investment Operations
Últimas notícias sobre a Ligand Pharmaceuticals
Ligand provides up to $47 million financing support to AvenCell Therapeutics
United StatesLigand acquires Ryjunea royalty rights for $23 million
United StatesLigand to acquire XOMA Royalty in $739M deal to bolster high-growth portfolio
United StatesFDA grants full approval to FILSPARI for FSGS, securing new royalty stream for Ligand
United States
Histórico de dividendos
Dividendos por ação pagos pela Ligand Pharmaceuticals, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2010 | — | — | — | $0.4560 |
| FY2007 | — | — | — | $9.3575 |
Principais indicadores financeiros
Resultados divulgados pela Ligand Pharmaceuticals, em USD.
- Cap. de mercado
- 6,2 bi
- Receita (TTM)
- 290,5 mi
- P/L
- 32.8
- LPA (diluído, TTM)
- 9.5
- Dividend yield
- —
- Margem de lucro
- 67.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 268,1 mi | 47,2 mi | 124,5 mi | |
| 167,1 mi | -22,6 mi | -4 mi | |
| 131,3 mi | 11,9 mi | 52,2 mi | |
| 196,2 mi | 3 mi | -33,4 mi |